冠心病合并2型糖尿病患者的调脂治疗
摘要
随着社会的发展、人们生活水平的提高和生活方式的改变，冠心病的发病率呈现出明显增加的趋势。冠心病因其高发病率和高死亡率，对人们的生活质量和生命安全形成了极大的威胁。在冠心病的众多危险因素中，血脂异常尤其是低密度脂蛋白胆固醇（LDL-C）升高，被认为与冠心病发病关系最为密切。
出处
《中国医学创新》
CAS
2009年第33期174-176,共3页
Medical Innovation of China
参考文献16
-
1Frank M. Sacks.After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study: Implications for Fenofibrate[J].The American Journal of Cardiology.2008(12)
-
2Rien ten Brinke,Nicky Dekker,Marjolein de Groot,David Ikkersheim.Lowering HbA1c in type 2 diabetics results in reduced risk of coronary heart disease and all-cause mortality[J].Primary Care Diabetes.2008(1)
-
3Jerome L. Fleg,Mihriye Mete,Barbara V. Howard,Jason G. Umans,Mary J. Roman,Robert E. Ratner,Angela Silverman,James M. Galloway,Jeffrey A. Henderson,Matthew R. Weir,Charlton Wilson,Mario Stylianou,Wm. James Howard.Effect of Statins Alone Versus Statins Plus Ezetimibe on Carotid Atherosclerosis in Type 2 Diabetes[J].Journal of the American College of Cardiology.2008(25)
-
4Nicola Abate,Alberico L. Catapano,Christie M. Ballantyne,Michael H. Davidson,Adam Polis,Steven S. Smugar,Andrew M. Tershakovec.Effect of ezetimibe/simvastatin versus atorvastatin or rosuvastatin on modifying lipid profiles in patients with diabetes, metabolic syndrome, or neither: Results of two subgroup analyses[J].Journal of Clinical Lipidology.2008(2)
-
5Ruth S. Weinstock,Ronald B. Goldberg,John R. Guyton,Theodore Mazzone,Adam Polis,Joanne E. Tomassini,Jianxin Lin,Arvind Shah,Andrew M. Tershakovec.Effect of ezetimibe/simvastatin vs atorvastatin on lowering levels of LDL-C and non–HDL-C, ApoB, and hs-CRP in patients with type 2 diabetes[J].Journal of Clinical Lipidology.2008(1)
-
6Alawi A. Alsheikh-Ali,Thomas A. Trikalinos,David M. Kent,Richard H. Karas.Statins, Low-Density Lipoprotein Cholesterol, and Risk of Cancer[J].Journal of the American College of Cardiology.2008(14)
-
7Matthew Silva,Michele L. Matthews,Courtney Jarvis,Nicole M. Nolan,Paul Belliveau,Michael Malloy,Pritesh Gandhi.Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy[J].Clinical Therapeutics.2007(2)
-
8Ivan Tká?.Treatment of dyslipidemia in patients with type 2 diabetes: Overview and meta-analysis of randomized trials[J].Diabetes Research and Clinical Practice.2007(3)
-
9Jennifer G. Robinson,Brian Smith,Nidhi Maheshwari,Helmut Schrott.Pleiotropic Effects of Statins: Benefit Beyond Cholesterol Reduction?[J].Journal of the American College of Cardiology.2005(10)
-
10Helen M Colhoun,D John Betteridge,Paul N Durrington,Graham A Hitman,H Andrew W Neil,Shona J Livingstone,Margaret J Thomason,Michael I Mackness,Valentine Charlton-Menys,John H Fuller.Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial[J].The Lancet.2004(9435)
-
1那开宪.治疗高血压应警惕他汀对血糖的影响[J].首都医药,2014(13):39-39. 被引量：1
-
2梁艺.冠心病多种危险因素分析[J].临床医学工程,2009,16(5):109-109. 被引量：1
-
3汪小萍,杜雪萍,段军,杨卉,李国刚.冠心病患者冠状动脉病变及其相关危险因素[J].临床医学,2007,27(10):57-58. 被引量：5
-
4秦嗣龙.格列美脲治疗新发老年2型糖尿病的疗效和安全性评价[J].河北医药,2014,36(1):104-105. 被引量：6
-
5王颖辉.儿童糖尿病及肥胖的预防[J].糖尿病天地（文摘刊）,2011(11):21-21.
-
6张文发.糖尿病慢性并发症的防治[J].科技广场,2003(1):46-47.
-
7巫翠华,宋冰,蔡绍曦.无创正压通气治疗重症社区获得性肺炎合并急性呼吸衰竭的疗效观察[J].实用临床医药杂志（护理版）,2010,14(12):20-22. 被引量：9
-
8唐亚娟.辛伐他汀不同剂量治疗冠心病的效果及安全性[J].中国疗养医学,2010,19(5):432-434. 被引量：5
-
9赵峰,姜秀贤.调脂治疗与冠心病一二级预防[J].社区卫生保健,2006,5(2):125-125.
-
10唐亚娟.辛伐他汀不同剂量治疗冠心病的效果及安全性[J].中国农村医学杂志,2010(1):9-10.
